FHN vs HLI

FHN presents a stark contrast between attractive valuation and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the current price of $24.21 is a discount to both the Graham Number ($28.16) and the growth-based Intrinsic Value ($58.7), the low health score and bearish insider activity suggest significant underlying risks. These concerns are partially offset by strong earnings growth (29.3% YoY) and a consistent track record of beating analyst estimates. Consequently, the stock is a high-risk value play where growth metrics clash with poor deterministic health indicators.

HLI exhibits a stable financial profile with a Piotroski F-Score of 4/9 and a very conservative debt-to-equity ratio of 0.22. While the current price of $159.71 is significantly above the Graham Number ($69.49), it remains well below the growth-based intrinsic value of $192.34, suggesting the market is pricing in high-quality growth. The company demonstrates exceptional earnings consistency, beating estimates in 3 of the last 4 quarters with strong YoY earnings growth of 22.3%. Despite bearish technicals and insider selling, the fundamental profitability and growth trajectory support a bullish long-term outlook.